Barclays analyst Andrew Mok lowered the firm’s price target on Centene (CNC) to $91 from $97 and keeps an Overweight rating on the shares post the Q3 report. While rates appear to be trending in the right direction, 1/1 rates remain the big swing factor in Medicaid margin progression and the company’s 2025 earnings growth, the analyst tells investors in a research note.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNC: